Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a significant drop in short interest in March. As of March 31st, there was short interest totaling 22,264 shares, a drop of 86.1% from the March 15th total of 160,544 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average daily volume of 289,557 shares, the short-interest ratio is presently 0.1 days.

Hedge Funds Weigh In On Cardio Diagnostics

An institutional investor recently raised its position in Cardio Diagnostics stock. DRW Securities LLC lifted its stake in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) by 122.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 40,463 shares of the company’s stock after purchasing an additional 22,298 shares during the quarter. DRW Securities LLC owned about 2.21% of Cardio Diagnostics worth $110,000 as of its most recent SEC filing. 8.06% of the stock is owned by institutional investors.

Cardio Diagnostics Stock Performance

CDIO stock traded up $0.02 during mid-day trading on Friday, reaching $1.83. 67,073 shares of the stock traded hands, compared to its average volume of 3,658,192. The business has a 50-day moving average price of $2.70 and a two-hundred day moving average price of $3.10. The stock has a market capitalization of $5.42 million, a PE ratio of -0.49 and a beta of 2.70. Cardio Diagnostics has a one year low of $0.97 and a one year high of $17.39.

Cardio Diagnostics (NASDAQ:CDIO) last released its earnings results on Friday, March 13th. The company reported ($0.80) earnings per share for the quarter. Cardio Diagnostics had a negative return on equity of 71.75% and a negative net margin of 40,612.50%. On average, equities analysts expect that Cardio Diagnostics will post -0.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardio Diagnostics in a research report on Monday, December 29th. Wall Street Zen raised Cardio Diagnostics to a “hold” rating in a research note on Saturday, March 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.